secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIGAND PHARMACEUTICALS INC (LGND)
CIK:        0000886163
Form:       8-K
Filed at:   2024-08-02T23:59:59+00:00
Accession:  0000886163-24-000064
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ligand Pharmaceuticals announces departure of President and COO Matthew Korenberg
--------------------------------------------------------------------------------

- Korenberg's employment ends no later than October 31, 2024; he may resign earlier in writing.
- Severance includes base salary through termination, 50% of 2024 target bonus, and COBRA coverage through Dec 31, 2024.
- Post-termination consulting agreement pays $47,808/mo through Oct 31, 2024, then reduced amounts.
- Stock award vesting continues through consulting period; unvested awards through Dec 31, 2025 accelerate on consulting end.
- Korenberg can exercise stock awards through March 1, 2026, subject to conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000064/0000886163-24-000064-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/886163/000088616324000064/lgnd-20240802.htm
  HTML page:      https://secwatch.observer/filing/0000886163-24-000064

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer